Bruker Corporation (BRKR)
| Previous close | 64.85 |
| Open | 64.70 |
| Bid | 65.23 x 400 |
| Ask | 65.60 x 400 |
| Day's range | 64.66 - 65.62 |
| 52-week range | 53.79 - 94.86 |
| Volume | |
| Avg. volume | 1,111,385 |
| Market cap | 9.911B |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 23.99 |
| EPS (TTM) | 2.73 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 0.20 (0.31%) |
| Ex-dividend date | 03 Jun 2024 |
| 1y target est | 81.21 |
Simply Wall St.Bruker's (NASDAQ:BRKR) 7.1% CAGR outpaced the company's earnings growth over the same five-year period
While Bruker Corporation ( NASDAQ:BRKR ) shareholders are probably generally happy, the stock hasn't had particularly...
ZacksBruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Business WireBruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
ANAHEIM, Calif., June 03, 2024--At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new Spectronaut 19 software and the novel PreOmics ENRICHplus kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics. Bruk
